Capricor Therapeutics Inc CAPR
Analyst Ratings
- Consensus
- Moderate Buy — 5 Buy · 3 Hold · 0 Sell (8 analysts)
- Avg. Price Target
- $35.00 (+426.3% upside)
Key Stats
- Today's Range
- $6.04 – $8.15
- 50-Day Range
- $2.96 – $30.93
- 52-Week Range
- $2.96 – $40.37
- Volume
- 66.33 million shs
- Average Volume
- 7.35 million shs
- Market Cap
- $242.65 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 2.66%
- Days to Cover
- 4.34
About Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Related Stocks
Compare head-to-head: CAPR vs LLY·CAPR vs JNJ·CAPR vs ABBV·CAPR vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.